SECsense Logo

Repare Therapeutics Inc. 8-K Report: Key Updates for Investors - February 2025

$RPTX
Form 8-K
Filed on: 2025-02-25
Source
Repare Therapeutics Inc. 8-K Report: Key Updates for Investors - February 2025

Based on the provided section of the financial report, here are the key extracted details and insights:

  1. Entity Information:
  • Company Name: Repare Therapeutics Inc.
  • CIK (Central Index Key): 0001808158
  • SEC File Number: 001-39335
  • Address: 7171 Frederick-Banting, Building 2 Suite 270, St-Laurent, QC, CA, H4S 1Z9
  • Phone Number: 857-412-7018
  1. Filing Information:
  • Type of Filing: 8-K (Current Report)
  • Filing Date: February 23, 2025
  1. Stock Information:
  • Common Shares: No par value
  • Ticker Symbol: RPTX
  • Exchange: NASDAQ
  1. Reporting Structure:
  • The report is filed under XBRL (eXtensible Business Reporting Language), which suggests that the company is adhering to modern reporting standards for financial statements.
  1. Period Covered:
  • Start Date of Reporting Period: February 23, 2025
  • End Date of Reporting Period: February 23, 2025
  • This indicates that it is a single-day report, possibly detailing a specific event or condition as required by the SEC.

Insights:

  • The filing type (8-K) generally indicates that the company is reporting significant events that shareholders should be aware of. It could involve material events such as acquisitions, changes in management, financial performance updates, etc.
  • The fact that this is a current report also emphasizes the urgency and relevance of the information contained within for investors and stakeholders.
  • Listing on NASDAQ and the provision of a CIK number show that Repare Therapeutics Inc. is a publicly traded company, subjected to regulatory oversight.

This information serves as a snapshot of the company's current status and relevant events as of the specified date, which is crucial for investors and analysts following the company’s performance and developments.